On May 16, 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) revealed its participation in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on May 21, 2025. This event signifies an important opportunity for Vanda to engage with investors and showcase their latest developments in the field of neurology and ophthalmology. This strategic move demonstrates Vanda's commitment to transparency and collaboration within the industry. Investors and stakeholders can look forward to gaining valuable insights into the company's future trajectory and advancements in the specified fields during the summit.